ORRs were substantially more favorable for trametinib than standard-of-care therapy in mutation-positive patients (50% vs 9%) compared to mutation-negative patients (8% vs 7%), although this difference did not reach statistical significance.
← all excerpts
Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine.
1
—
—